(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 July 2011 (28.07.2011)

PCT

(10) International Publication Number
WO 2011/089183 A2

(51) International Patent Classification:
A61K 39/00 (2006.01) *C07K 16/44* (2006.01)

(21) International Application Number:
PCT/EP2011/050749

(22) International Filing Date:
20 January 2011 (20.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10151239.0 20 January 2010 (20.01.2010) EP
61/383,914 17 September 2010 (17.09.2010) US

(71) Applicant *(for all designated States except US)*: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **VAN RYN, Joanne** [CA/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **PARK, John Edward** [US/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **HAUEL, Norbert** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **KUNZ, Ulrich** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **LITZENBURGER, Tobias** [DE/DE]; Boehringer Ingelheim GmbH, Corporate Patents, Binger Str. 173, 55216 Ingelheim am Rhein (DE). **CANADA, Keith** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 (US). **SINGH, Sanjaya** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 (US). **WATERMAN, Alisa** [US/US]; Boehringer Ingelheim Pharmaceuticals, Inc., 900 Ridgebury Road, Ridgefield, CT 06877 (US).

(74) Agents: **HAMMANN, Heinz** et al.; c/o Boehringer Ingelheim GmbH, Binger Str. 173, 55216 Ingelheim am Rhein (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH,

[Continued on next page]

(54) Title: ANTICOAGULANT ANTIDOTES




FIGURE 8

(57) Abstract: The present invention relates to antibody molecules against anticoagulants, in particular dabigatran, and their use as antidotes of such anticoagulants.

WO 2011/089183 A2

GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*